MDWD vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYRE
Should you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
MediWound vs. Its Competitors
Oculis (NASDAQ:OCS) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
22.3% of Oculis shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Oculis has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
In the previous week, MediWound had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for MediWound and 1 mentions for Oculis. MediWound's average media sentiment score of 0.40 beat Oculis' score of 0.00 indicating that MediWound is being referred to more favorably in the news media.
MediWound has a net margin of -110.45% compared to Oculis' net margin of -13,788.70%. MediWound's return on equity of -74.12% beat Oculis' return on equity.
MediWound has higher revenue and earnings than Oculis. MediWound is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.
Oculis presently has a consensus price target of $35.33, suggesting a potential upside of 88.55%. MediWound has a consensus price target of $31.80, suggesting a potential upside of 65.02%. Given Oculis' higher possible upside, research analysts plainly believe Oculis is more favorable than MediWound.
Summary
MediWound beats Oculis on 12 of the 14 factors compared between the two stocks.
Get MediWound News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediWound Competitors List
Related Companies and Tools
This page (NASDAQ:MDWD) was last updated on 7/8/2025 by MarketBeat.com Staff
Free MDWD Stock Alerts